Novartis Touts Ligelizumab As Xolair Successor In CSU

Filing Planned For 2021

 
• By Kevin Grogan
  
Dog_Podium
Novartis hopes ligelizumab will be top dog for CSU • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Dermatological

More from Therapeutic Category